Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Patients with ADHD only or ADHD and Dyslexia

• At least 10 years old and no more than 16 years old

• IQ score of 80 or more

• Must be able to swallow capsules

Exclusion Criteria:

• Have received treatment within last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry

• Weigh less than 25 kg or greater than 70 kg

• Pregnant or breast feeding

• Documented history of bipolar I or II disorder, or psychosis

• Documented history of autism, Asperger's syndrome or pervasive developmental disorder